Increasing Popularity Of Oral Treatments For Cancer Highlights Importance Of Patient Medical Adherence
Study published in Drug And Alcohol Dependence finds that voucher incentives increase medical adherence and improve anti-retrovirus therapy for methadone users with HIV and AIDS
New Haven, CT - February 24, 2009 - Anti-retrovirus therapy for HIV and AIDS patients requires close medical adherence to achieve optimal results. However, the rigorous nature of the medication program often leads to significant instances medical non-adherence and escalated disease progression, especially among patients who are injection drug users or methadone patients. A new study in the February 2009 issue of the international journal Drug and Alcohol Dependence explored the effect of voucher incentives on medical compliance during a 12-week intervention.
The study, "Effect of incentives for medication adherence on health care use and costs in methadone patients with HIV," gave a group of non-compliant HIV patients regular voucher incentives for following their medication regiment exactly, while a second control group did not receive incentives for following their doctors' treatment plan. Over three months, the group given vouchers was 78% compliant, while the control group was 56% compliant.
"As the medical community searches for new solutions to medical non-adherence, this new data on the efficacy of incentive-driven programs is promising to those struggling with chronic diseases, to the health professionals treating them and to the marketers thinking practically about the success of an adherence program," said Kevin Aniskovich, Chief Executive of the healthcare information technology company Intelecare, which specializes medical reminder solutions. “This study also reinforces the need for customizing compliance programs by patient populations with special needs and lifestyles and ending the days of the the flawed 'one-size-fits-all' mentality to project design."
Although the study found that incentives significantly improve medical compliance, the text v. control design indicates statistically significant results and opens the doors to continued outreach to demonstrate the long-term effect of incentives-based programs. However, researchers did conclude that if the incentives did continue to improve adherence, long-term medical benefits would be seen and disease progression would slow. The researchers are also calling for more information concerning how much a working real-world incentive program might cost and further evaluation regarding how future programs could lower costs.
To read the study in full, please visit http://www.drugandalcoholdependence.com
Established in 2005, Intelecare Compliance Solutions is a privately owned healthcare information technology company that provides an array of practical tools and services promoting medical adherence. With 84 percent of patients reporting forgetfulness as the major cause of non-compliance, and with the healthcare system suffering over $300 billion in costs annually due to non-compliance, Intelecare's solutions enable patients and caregivers alike to keep track of medications, doses, and doctor's appointments through the phone, mobile devices, and email - all while keeping simplicity, practicality, and innovation at the heart of its developments.
Aside from individual end-user services, Intelecare provides and manages a suite of scalable services for insurers, employers, retail pharmacies, non-profit organizations and pharmaceutical manufacturers. Currently supporting millions of subscribers, Intelecare is dedicated to finding functional solutions to the widespread issue of medical non-compliance for individuals around the world that work the way people live.
Intelecare in the News: Founder and CEO named to Top 100 people in Life-Sciences industry.
Click here to read more.
*Intelecare is a trademark of Intelecare Compliance Solutions, Inc. All other trademarks are the property of their respective owners.